Donor screening for human T-cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity

American Journal of Transplantation

Volumn 10, Issue 2, 2010, Pages 207-213

  Kaul, D R ^a   Taranto, S ^b   Alexander, C ^c   Covington, S ^b   Marvin, M ^d   Nowicki, M ^e   Orlowski, J ^f   Pancoska, C ^g   Pruett, T L ^h   Ison, M G ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNITED NETWORK FOR ORGAN SHARING   (United States)

^c Living Legacy Foundation of Maryland   (United States)

^d JEWISH HOSPITAL   (United States)

^e National Institute of Transplantation Los Angeles   (United States)

^f Center for Donation and Transplant   (United States)

^g LABS Inc   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Donor evaluation; Donor to host transmission; Infectious diseases; Viral infection

Indexed keywords

ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INCIDENCE; NEUROLOGIC DISEASE; ORGAN DONOR; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; UNITED STATES;

DONOR SELECTION; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; UNITED STATES; VIRUSES;

EID: 75149130418     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02867.x     Document Type: Short Survey

References (28)

1. Blattner WA, Saxinger C, Riedel D et al. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990 3 : 1102 1108.
2. Glynn SA, Kleinman SH, Schreiber GB et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in U.S. blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000 284 : 229 235.
3. Manns A, Wilks RJ, Murphy EL et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992 51 : 886 891.
4. Martin-Davila P, Fortun J, Lopez-Velez R et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008 21 : 60 96.
5. Murphy E, Roucoux D. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004 6 : 144 154.
6. Nowicki MJ, Matsuoka L, Brucal D et al. High seroprevalence of anti-HTLV-I/II antibodies among solid organ donors necessitates confirmatory testing. Transplantation 2006 82 : 1210 1213.
7. Shames BD, D'Alessandro AM, Sollinger HW. Human T-cell lymphotrophic virus infection in organ donors: A need to reassess policy? Am J Transplant 2002 2 : 658 663.
8. U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. Available from : http://optn.transplant.hrsa.gov/ policiesAndBylaws/policies.asp. Accessed April 23, 2009.
9. US Food and Drug Administrations. Center for Biologics Evaluation and Research. [cited 2009 April 24]; Available from : http://www.fda.gov/cber/ tissue/prod.htm#approved
10. Ison MG, Pruett T, Teperman L. Current practices and future challenges: A survey reported by the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee. In : American Transplantation Congress : 385 Abstract. Boston, 2009.
11. Package Insert: Abbott PRISM HTLV-II/HTLV-II.
12. Package Insert: Abbott HTLV-I/HTLV-II EIA.
13. Package Insert: BioMerieux Vironostika HTLV-I/II Microelisa System.
14. Nakatsuji Y, Sugai F, Watanabe S et al. HTLV-I-associated myelopathy manifested after renal transplantation. J Neurol Sci 2000 177 : 154 156.
15. Remesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV-I by kidney transplant. Transfusion 2000 40 : 1421 1422.
16. Toro C, Rodés B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003 75 : 102 104.
17. Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001 91 : 869 875.
18. Kawano N, Shimoda K, Ishikawa F et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006 82 : 840 843.
19. Nakamura N, Arakaki Y, Sunagawa H et al. Influence of immunosuppression in HTLV-1-positive renal transplant recipients. Transpl Proc 1998 30 : 1324 1326.
20. Tanabe K, Kitani R, Takahashi K et al. Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Transpl Proc 1998 30 : 3168 3170.
21. Marvin MR, Brock GN, Kwarteng K et al. Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: Is it safe? Transplantation 2009 87 : 1180 1190.
22. Claquin J, Romano P, Noury D et al. Human T lymphotropic virus 1 - 2 positive antibodies in potential organ donors in France. Transpl Proc 1996 28 : 189 190.
23. Toro C, Benito R, Aguilera A et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005 76 : 268 270.
24. Harrington WJ Jr., Ucar A, Gill P et al. Clinical spectrum of HTLV-I in south Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995 8 : 466 473.
25. Levine PH, Dosik H, Joseph EM et al. A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn. Int J Cancer 1999 80 : 662 666.
26. Personal communication, National Institute of Transplantation, Inc., 2009.
27. Personal communication, Carol Pancoska, LABS-Inc., 2009.
28. Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV-I-positive renal transplant recipients. Transpl Proc 2005 37 : 1779 1782.